<DrugInformationSummary id="CDR0000817185"><DrugInfoMetaData><DrugInfoType>Brief</DrugInfoType><DrugInfoAudience>Patients</DrugInfoAudience><DrugInfoDescription>Revumenib citrate works by binding to a protein called menin. This prevents menin from interacting with  a rearranged form of the KMT2A protein made by an abnormal KMT2A gene found in some leukemia cells. Blocking the interaction between menin and the rearranged KMT2A protein helps slow or stop the growth of leukemia cells. Revumenib citrate is a type of targeted therapy called a menin inhibitor.</DrugInfoDescription><DrugInfoURL xref="https://www.cancer.gov/about-cancer/treatment/drugs/revumenib-citrate">Revumenib Citrate</DrugInfoURL><FDAApproved>Yes</FDAApproved><TerminologyLink ref="CDR0000800199">revumenib citrate</TerminologyLink><GlossaryLink ref="CDR0000817140">revumenib citrate</GlossaryLink><USBrandNames><USBrandName>Revuforj</USBrandName></USBrandNames><PronunciationInfo><TermPronunciation>reh-VOO-meh-nib SIH-trayt</TermPronunciation><MediaLink ref="CDR0000817793" type="audio/mpeg" alt="" language="en" id="_3"/><MediaLink ref="CDR0000817794" type="audio/mpeg" alt="" language="es" id="_4"/></PronunciationInfo><FDAExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6eb3cdbc-0e74-477d-82d6-3bb172d3f63f&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</FDAExternalRef></DrugInfoMetaData><DrugInfoTitle>Revumenib Citrate</DrugInfoTitle><Section id="_FDA"><Para><ExternalRef xref="https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=6eb3cdbc-0e74-477d-82d6-3bb172d3f63f&amp;audience=consumer">FDA label information for this drug is available at DailyMed.</ExternalRef></Para></Section><Section id="_1"><Title>Use in Cancer</Title>                                                              
  <Para id="_2">Revumenib citrate
         is approved to treat adults and children aged 1 year and older with:</Para>                          
  <ItemizedList Style="bullet" id="_3">
   <ListItem><Strong><GlossaryTermRef href="CDR0000045145" dictionary="Cancer.gov" audience="Patient">acute leukemia</GlossaryTermRef></Strong> that has an abnormal <GeneName>KMT2A</GeneName> gene and has come back or did not respond to previous treatment</ListItem>
   </ItemizedList>
  <Para id="_4">Revumenib citrate
         is also being studied in the treatment of other types of
         cancer.</Para>
 </Section><Section id="_About"><Title>More About Revumenib Citrate</Title><Para id="_Dict_1"><ExternalRef xref="https://www.cancer.gov/publications/dictionaries/cancer-drug/def/800199">Definition from the NCI Drug Dictionary</ExternalRef> - Detailed scientific definition and other names for this drug.</Para></Section><Section id="_Research"><Title>Research Results and Related Resources</Title><Para><ExternalRef xref="https://www.cancer.gov/about-cancer/treatment/types/targeted-therapies">Targeted Therapy to Treat Cancer</ExternalRef></Para></Section><Section id="_ClinicalTrial_1"><Title>Clinical Trials Accepting Patients</Title><Para id="_ClinicalTrial_2"><ExternalRef xref="https://www.cancer.gov/research/participate/clinical-trials/intervention/C204149">Find Clinical Trials for Revumenib Citrate</ExternalRef> - Check for trials from NCI's list of cancer clinical trials now accepting patients.</Para></Section> 
  <DrugInfoDisclaimer>


<Para id="_Disclaimer_4"><Strong>Important: </Strong>The drug information on this page is meant to be educational. It is not a substitute for medical advice. The information may not cover all possible uses, actions, interactions, or side effects of this drug, or precautions to be taken while using it. Please see your health care professional for more information about your specific medical condition and the use of this drug.
</Para></DrugInfoDisclaimer> 
  <DateFirstPublished>2024-12-03</DateFirstPublished></DrugInformationSummary>
